Copyright
©The Author(s) 2018.
World J Gastroenterol. Nov 7, 2018; 24(41): 4691-4697
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4691
Published online Nov 7, 2018. doi: 10.3748/wjg.v24.i41.4691
Table 1 Baseline characteristics of 492175 nationally estimated discharges in the Nationwide Inpatient Sample from 2011 to 2013 who underwent endoscopic retrograde cholangiopancreatography comparing end-stage renal disease and chronic kidney disease to control group without renal disease n (%)
| ESRD, n = 7347 | Control, n = 445424 | P value | CKD, n = 39403 | P value | |
| Age, mean (SE), yr | 65.5 (0.42) | 58 (0.12) | < 0.001 | 75.35 (0.18) | < 0.001 |
| Female | 3477 (47.3) | 271300 (61) | < 0.001 | 17626 (44.7) | < 0.001 |
| Race | < 0.001 | < 0.001 | |||
| White | 3221 (43.8) | 280738 (63) | 26905 (68.3) | ||
| Black | 1520 (20.7) | 36875 (8.3) | 3517 (8.9) | ||
| Hispanic | 1467 (20) | 68492 (15.4) | 3729 (9.5) | ||
| Asian/Pacific Islander | 454 (6.2) | 14081 (3.2) | 1466(3.7) | ||
| Native American | 105 (1.4) | 2828 (0.6) | 185 (0.5) | ||
| Other | 235 (3.2) | 14928 (3.3) | 982 (2.5) | ||
| Missing | 344 (4.7) | 27483 (6.2) | 2619 (6.6) | ||
| Charlson comorbidity index | < 0.001 | < 0.001 | |||
| 0 | 0 | 203229 (45.6) | 0 (0) | ||
| 1 | 0 | 104584 (23.5) | 0 (0) | ||
| 2 | 975 (13.3) | 55808 (12.5) | 6417 (16.3) | ||
| > 2 | 6372 (86.7) | 81804 (18.4) | 32986 (83.7) | ||
| Coagulopathy | 668 (9) | 15102 (3.4) | < 0.001 | 2633 (6.7) | < 0.001 |
| ERCP indication | < 0.001 | < 0.001 | |||
| Diagnostic | 1990 (27) | 102074 (22.9) | 9493 (24.1) | ||
| Therapeutic | 5257 (73) | 343350 (77.1) | 29910 (75.9) | ||
| Health insurance | < 0.001 | < 0.001 | |||
| Medicare | 5655 (77) | 189044 (42.7) | 31759 (80.7) | ||
| Medicare | 923 (9.9) | 59219 (13.4) | 1718 (4.4) | ||
| Private | 827 (11.3) | 142807 (32.3) | 4766 (12) | ||
| Self-pay | 40 (0.5) | 32785 (7.4) | 463 (1.2) | ||
| Others | 92 (1.3) | 18822 (4.2) | 670 (1.7) |
Table 2 In-hospital complications after endoscopic retrograde cholangiopancreatography from 2011 to 2013 based on data from the Nationwide Inpatient Sample comparing end-stage renal disease to controls n (%)
| Type of complications | ESRDn = 7347 | Controln = 445424 | CrudeOR/MD (95%CI) | AdjustedOR/MD (95%CI) | AdjustedP value |
| Death | 526 (7.1) | 5138 (1.15) | 6.6 (5.3-8.2) | 3.7 (2.9–4.6) | < 0.001 |
| Pancreatitis | 611 (8.3) | 20315 (4.6) | 1.9 (1.6-2.3) | 1.7 (1.4-2.1) | < 0.001 |
| Bleeding | 377 (5.1) | 6546 (1.5) | 3.6 (2.86-4.59) | 1.86 (1.4-2.4) | < 0.001 |
| Perforation | 14 (0.2) | 340 (0.07) | 2.6 (0.8–8.4) | 3 (0.86–10.00) | 0.08 |
| Length of hospital stay, mean days (SE) | 13 (0.46) | 6 (0.03) | 7.2 (6.4-8.0) | 5.9 (5.0-6.7) | < 0.001 |
Table 3 In-hospital complications after endoscopic retrograde cholangiopancreatography from 2011 to 2013 based on data from the Nationwide Inpatient Sample comparing chronic kidney disease to controls n (%)
| Type of complications | CKDn = 39403 | Controln = 445424 | CrudeOR/MD (95%CI) | AdjustedOR/MD (95%CI) | AdjustedP value |
| Death | 1176 (3) | 5138 (1.15) | 2.6 (2.3-3.0) | 1.3 (1.14-1.55) | 0.001 |
| Pancreatitis | 750 (6.8) | 20315 (4.6) | 1.5 (1.3-1.6) | 1.5 (1.3-1.7) | < 0.001 |
| Bleeding | 1454 (3.7) | 6546 (1.5) | 2.56 (2.25–2.90) | 1.4 (1.2-1.6) | < 0.001 |
| Perforation | 43 (0.1) | 340 (0.07) | 1.4 (0.7–2.9) | 1.36 (0.6–3.2) | 0.5 |
| Length of hospital stay, mean days (SE) | 8.5 (0.11) | 6 (0.03) | 2.45 (2.24-2.67) | 1.4 (1.20-1.65) | < 0.001 |
- Citation: Sawas T, Bazerbachi F, Haffar S, Cho WK, Levy MJ, Martin JA, Petersen BT, Topazian MD, Chandrasekhara V, Abu Dayyeh BK. End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients. World J Gastroenterol 2018; 24(41): 4691-4697
- URL: https://www.wjgnet.com/1007-9327/full/v24/i41/4691.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i41.4691